Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study

BACKGROUND: The NORDIC-VII study is a randomised phase III trial of cetuximab plus continuous or intermittent fluorouracil, folinic acid, and oxaliplatin (Nordic FLOX) vs FLOX alone in first-line treatment of metastatic colorectal cancer. The present report presents an updated and final survival ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Guren, Tormod Kyrre, Thomsen, Maria, Kure, Elin H, Sorbye, Halfdan, Glimelius, Bengt, Pfeiffer, Per, Österlund, Pia, Sigurdsson, Fridbjörn, Lothe, Inger Marie Bowitz, Dalsgaard, Astrid Marie, Skovlund, Eva, Christoffersen, Thoralf, Tveit, Kjell Magne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482736/
https://www.ncbi.nlm.nih.gov/pubmed/28399112
http://dx.doi.org/10.1038/bjc.2017.93

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482736/
https://www.ncbi.nlm.nih.gov/pubmed/28399112
http://dx.doi.org/10.1038/bjc.2017.93

Ejemplares similares